Kwality Pharma vs SMS Pharma vs Panacea Biotec: Which Stock Should You Track

Kwality Pharmaceuticals vs SMS Pharmaceuticals vs Panacea Biotec starts with the core numbers most investors compare within the pharma formulations segment: market capitalisation, valuation multiples, profitability, dividend yield and the latest quarterly results. Figures below are sourced as of October 2026 and will shift with daily price moves.

All three names sit in the pharma formulations bucket, which makes them a natural set to place side by side rather than a random trio of unrelated businesses. The sections below cover the company profiles, a valuation table, the latest quarter and a five-quarter trend for revenue and net profit.

Click Here – Get Free Investment Predictions

Kwality Pharmaceuticals, SMS Pharmaceuticals and Panacea Biotec: Company Overview

Kwality Pharmaceuticals is a listed Indian company in the pharma formulations space, tracked here on book value, return ratios and valuation alongside its peers in this comparison. It has a market capitalisation of about Rs 3,663 crore, a return on equity of 20.31% and a book value of Rs 318.80 per share. Its quarterly revenue moved from Rs 111.86 crore in June 2025 to Rs 162.97 crore in June 2026, a change of +45.7%.

SMS Pharmaceuticals is a listed Indian company in the pharma formulations space, tracked here on book value, return ratios and valuation alongside its peers in this comparison. It has a market capitalisation of about Rs 4,100 crore, a return on equity of 12.98% and a book value of Rs 83.91 per share. Its quarterly revenue moved from Rs 196.64 crore in June 2025 to Rs 208.70 crore in June 2026, a change of +6.1%.

Panacea Biotec is a listed Indian company in the pharma formulations space, tracked here on book value, return ratios and valuation alongside its peers in this comparison. It has a market capitalisation of about Rs 2,138 crore, a return on equity of -2.93% and a book value of Rs 132.76 per share. Its quarterly revenue moved from Rs 172.37 crore in June 2025 to Rs 203.81 crore in June 2026, a change of +18.2%.

Kwality Pharmaceuticals vs SMS Pharmaceuticals vs Panacea Biotec: Valuation and Profitability Snapshot

Metric	Kwality Pharmaceuticals	SMS Pharmaceuticals	Panacea Biotec
Market Cap (approx.)	Rs 3,663 crore	Rs 4,100 crore	Rs 2,138 crore
PE Ratio (TTM)	45.20	40.05	NA
PB Ratio	11.07	5.22	2.63
Return on Equity (ROE)	20.31%	12.98%	-2.93%
EPS (TTM, Rs)	78.11	10.93	-1.46
Dividend Yield	0.00%	0.09%	0.00%
Debt to Equity	0.39	0.46	0.03
Book Value per Share (Rs)	318.80	83.91	132.76

Check the Univest Screener for Live Data

On valuation, Kwality Pharmaceuticals trades at a PE of 45.20 and a PB of 11.07, SMS Pharmaceuticals at a PE of 40.05 and a PB of 5.22, while Panacea Biotec trades at a PE of NA and a PB of 2.63. On return on equity, the three post 20.31%, 12.98% and -2.93% respectively, and on dividend yield they stand at 0.00%, 0.09% and 0.00%. SMS Pharmaceuticals has the highest market capitalisation of the three at Rs 4,100 crore, while Panacea Biotec has the lowest at Rs 2,138 crore. Kwality Pharmaceuticals has the highest PE ratio of the three at 45.20, while SMS Pharmaceuticals has the lowest at 40.05. Kwality Pharmaceuticals has the highest return on equity of the three at 20.31%, while Panacea Biotec has the lowest at -2.93%. SMS Pharmaceuticals has the highest debt to equity ratio of the three at 0.46, while Panacea Biotec has the lowest at 0.03. Debt to equity is 0.39, 0.46 and 0.03 for the three respectively.

Kwality Pharmaceuticals vs SMS Pharmaceuticals vs Panacea Biotec: Latest Quarterly Results

Company	Latest Quarter Revenue	Latest Quarter Net Profit	YoY Change (Revenue)	QoQ Change (Revenue)	YoY Change (Net Profit)
Kwality Pharmaceuticals	Rs 162.97 crore	Rs 25.62 crore	+45.7%	+3.0%	+114.9%
SMS Pharmaceuticals	Rs 208.70 crore	Rs 20.20 crore	+6.1%	-13.2%	+8.0%
Panacea Biotec	Rs 203.81 crore	Rs 2.20 crore	+18.2%	+20.4%	-44.4%

Quarterly figures above are the most recent reported quarter for each company (Q1 FY27, quarter ended June 2026), compared with the year-ago and preceding quarter. A percentage change in net profit is shown as NA where the comparison quarter was a loss or the latest quarter is a loss, since the percentage is not meaningful in that case.

Kwality Pharmaceuticals vs SMS Pharmaceuticals vs Panacea Biotec: Five-Quarter Revenue and Net Profit Trend

The five-quarter view below shows how revenue and net profit moved from June 2025 to June 2026 for each company in Kwality Pharmaceuticals vs SMS Pharmaceuticals vs Panacea Biotec, which helps separate a one-quarter move from a steadier pattern.

Quarterly revenue (Rs crore)

Quarter	Kwality Pharmaceuticals	SMS Pharmaceuticals	Panacea Biotec
June 2025	Rs 111.86 crore	Rs 196.64 crore	Rs 172.37 crore
September 2025	Rs 111.95 crore	Rs 243.86 crore	Rs 147.53 crore
December 2025	Rs 123.97 crore	Rs 214.20 crore	Rs 167.47 crore
March 2026	Rs 158.17 crore	Rs 240.52 crore	Rs 169.30 crore
June 2026	Rs 162.97 crore	Rs 208.70 crore	Rs 203.81 crore

Quarterly net profit (Rs crore)

Quarter	Kwality Pharmaceuticals	SMS Pharmaceuticals	Panacea Biotec
June 2025	Rs 11.92 crore	Rs 18.71 crore	Rs 3.96 crore
September 2025	Rs 14.12 crore	Rs 25.13 crore	-Rs 14.01 crore
December 2025	Rs 16.00 crore	Rs 23.19 crore	Rs 3.89 crore
March 2026	Rs 25.31 crore	Rs 20.96 crore	-Rs 1.00 crore
June 2026	Rs 25.62 crore	Rs 20.20 crore	Rs 2.20 crore

Kwality Pharmaceuticals reported revenue of Rs 111.86 crore in June 2025 and Rs 162.97 crore in June 2026, a change of +45.7% across the period. Its highest quarterly revenue in this window was Rs 162.97 crore in June 2026. Net profit stood at Rs 25.62 crore in June 2026, which is a net profit margin of 15.72%.

SMS Pharmaceuticals reported revenue of Rs 196.64 crore in June 2025 and Rs 208.70 crore in June 2026, a change of +6.1% across the period. Its highest quarterly revenue in this window was Rs 243.86 crore in September 2025. Net profit stood at Rs 20.20 crore in June 2026, which is a net profit margin of 9.68%.

Panacea Biotec reported revenue of Rs 172.37 crore in June 2025 and Rs 203.81 crore in June 2026, a change of +18.2% across the period. Its highest quarterly revenue in this window was Rs 203.81 crore in June 2026. Net profit stood at Rs 2.20 crore in June 2026, which is a net profit margin of 1.08%. Panacea Biotec reported a net loss in September 2025 and March 2026.

Download the Univest iOS App or Univest Android App to track Kwality Pharmaceuticals, SMS Pharmaceuticals and Panacea Biotec live prices.

What Should Investors Look at Beyond These Numbers?

Beyond the metrics above, investors comparing these three pharma formulations names should track quarter-on-quarter revenue and margin trends, management commentary on demand and cost drivers, and factors specific to the segment such as regulatory approvals, export orders, product mix, raw material costs and capacity utilisation. A single-quarter snapshot can shift quickly, and smaller companies in particular can show wide swings from one quarter to the next.

It also helps to read the latest quarterly filings and investor presentations of Kwality Pharmaceuticals, SMS Pharmaceuticals and Panacea Biotec directly, since the figures here come from standardised data and do not capture company-specific context such as one-time items, order timing or promoter actions.

Conclusion

Kwality Pharmaceuticals vs SMS Pharmaceuticals vs Panacea Biotec highlights how differently three companies in the same pharma formulations segment can look across valuation, profitability and dividend metrics, even when operating in a similar space. This comparison does not declare a winner; investors should weigh these figures against their own research and risk appetite. Please read the disclaimer below before making any investment decision.

FAQs on Kwality Pharmaceuticals vs SMS Pharmaceuticals vs Panacea Biotec

What is the market cap difference between Kwality Pharmaceuticals, SMS Pharmaceuticals and Panacea Biotec?

Ans. As of October 2026, Kwality Pharmaceuticals has a market cap of approximately Rs 3,663 crore, SMS Pharmaceuticals is at approximately Rs 4,100 crore, and Panacea Biotec is at approximately Rs 2,138 crore.

What are the PE and PB ratios of Kwality Pharmaceuticals, SMS Pharmaceuticals and Panacea Biotec?

Ans. As of October 2026, the PE ratios stand at 45.20, 40.05 and NA respectively, and the price to book ratios stand at 11.07, 5.22 and 2.63 respectively.

Which of the three has the highest ROE?

Ans. Kwality Pharmaceuticals, SMS Pharmaceuticals and Panacea Biotec post ROE of 20.31%, 12.98% and -2.93% respectively as of October 2026. Kwality Pharmaceuticals has the highest return on equity of the three at 20.31%, while Panacea Biotec has the lowest at -2.93%.

Which of these three stocks pays the highest dividend yield?

Ans. Kwality Pharmaceuticals, SMS Pharmaceuticals and Panacea Biotec carry dividend yields of 0.00%, 0.09% and 0.00% respectively.

What is the debt to equity ratio for Kwality Pharmaceuticals, SMS Pharmaceuticals and Panacea Biotec?

Ans. Kwality Pharmaceuticals carries a debt to equity of 0.39, SMS Pharmaceuticals of 0.46, and Panacea Biotec of 0.03.

What were the latest quarterly revenue and net profit of Kwality Pharmaceuticals, SMS Pharmaceuticals and Panacea Biotec?

Ans. For Q1 FY27 (quarter ended June 2026), Kwality Pharmaceuticals reported revenue of Rs 162.97 crore and net profit of Rs 25.62 crore, SMS Pharmaceuticals reported revenue of Rs 208.70 crore and net profit of Rs 20.20 crore, and Panacea Biotec reported revenue of Rs 203.81 crore and net profit of Rs 2.20 crore.

Does this comparison recommend one of Kwality Pharmaceuticals, SMS Pharmaceuticals and Panacea Biotec?

Ans. This comparison does not declare one stock ahead of another; each company scores differently across valuation, profitability and dividend metrics, and the right fit depends on an individual investor's own criteria and research.